CERVAVAC receives WHO prequalification
Serum Institute of India’s CERVAVAC, the country’s first indigenously developed gender-neutral quadrivalent human papillomavirus vaccine, has received prequalification from the World Health Organization (WHO)
CERVAVAC, India’s first indigenously developed gender-neutral Quadrivalent Human Papillomavirus vaccine (qHPV) developed by Serum Institute of India, has received prequalification by the World Health Organization (WHO).
This is the 32nd WHO prequalification for products/biologicals received by Serum Institute of India. Inclusion on the WHO List of Prequalified Vaccines allows CERVAVAC to be procured by United Nations agencies.
The recombinant quadrivalent HPV vaccine targets HPV types 6, 11, 16 and 18. It is indicated for girls and boys aged 9 through 26 years.
Adar Poonawalla, Chief Executive Officer, Serum Institute of India, said, “WHO prequalification of CERVAVAC is an important step in strengthening the global response to HPV. This milestone reflects the effectiveness of the vaccine and creates the opportunity for countries to prevent HPV-related risks. We are pleased to see this indigenously developed vaccine reach this achievement, and look forward to contributing to immunisation coverage, advancing global healthcare”
CERVAVAC was previously approved for use in India by the Drugs Controller General of India (DCGI). It is administered for the prevention of diseases caused by the four HPV types.
This includes the prevention of anal cancer in boys and young men, and cervical, vulvar, vaginal, and anal cancers in girls and young women. It is also indicated for preventing genital warts, as applicable to the indicated population.